Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 48,491 shares, an increase of 279.3% from the June 30th total of 12,783 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 388,731 shares, the short-interest ratio is currently 0.1 days.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Finally, Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy”.
View Our Latest Stock Report on Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. Unsponsored ADR Stock Performance
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. The firm had revenue of $881.71 million for the quarter, compared to analysts’ expectations of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%. On average, research analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.79 EPS for the current year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
See Also
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
